Vedolizumab-Induced Photosensitivity: An Underreported Phenomenon?

Authors

  • Beatriz F. Vilela Dermatovenerology Department. Hospital Santo António dos Capuchos. Unidade Local de Saúde São José. Lisbon. https://orcid.org/0009-0004-4492-9214
  • Clara Valente Dermatovenerology Department. Hospital Santo António dos Capuchos. Unidade Local de Saúde São José. Lisbon. https://orcid.org/0000-0001-6910-9248
  • José M. Neves Dermatovenerology Department. Hospital Santo António dos Capuchos. Unidade Local de Saúde São José. Lisbon. https://orcid.org/0000-0002-9014-2031
  • Gabriela M. Pinto Dermatovenerology Department. Hospital Santo António dos Capuchos. Unidade Local de Saúde São José. Lisbon.
  • Virgínia Coelho de Sousa Dermatovenerology Department. Hospital de São Camilo. Portimão.

DOI:

https://doi.org/10.20344/amp.22512

Keywords:

Antibodies, Monoclonal, Humanized/adverse effects, Inflammatory Bowel Diseases/drug therapy, Photosensitivity Disorders/chemically induced

Abstract

n/a.

Downloads

Download data is not yet available.

References

Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158:562-72.e12.

Bergqvist V, Holmgren J, Klintman D, Marsal J. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55:1389-1401.

Dao D, Agarwal V, Srivastava P, Powell J, Kalavala M. P98 Biologic-induced photosensitivity: a case of three. Br J Dermatol. 2022;187:S31–83.

Downloads

Published

2026-02-02

How to Cite

1.
Vilela BF, Valente C, Neves JM, M. Pinto G, Coelho de Sousa V. Vedolizumab-Induced Photosensitivity: An Underreported Phenomenon?. Acta Med Port [Internet]. 2026 Feb. 2 [cited 2026 Mar. 19];39(2):163-4. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/22512

Issue

Vol. 39 No. 2 (2026): February

Section

Letters to the Editor

License

Copyright (c) 2026 Acta Médica Portuguesa

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.

Crossref
Scopus
Google Scholar
Europe PMC